A PHASE 2, INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) ALONE AND IN COMBINATION WITH DURVALUMAB (MEDI4736) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTION OR DECITABINE
You are being asked to take part in this study because you have myelodysplastic syndrome (MDS) and received decitabine or azacitidine by injection but the disease did not improve or you did not tolerate the treatment well. The goal of this clinical research study is to learn if CC-486 alone or in combination with MEDI4736 (durvalumab) can help to control MDS. The safety of CC-486 alone and in combination with durvalumab will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 07/17/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: